Therapeutic Asset Ratings
6,308 results matching 1 filter
91,564 assets · 7,904 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
FULVESTRANT
Squamous Cell Lung Carcinoma
Terremoto Biosciences Inc.
P1/2
CCC
(48)
FULVESTRANT
Carcinoma
Memorial Sloan Kettering Cancer Center
P1/2
CCC
(48)
Gabapentin
Head And Neck Carcinoma
Natalie Lockney
P1/2
CCC
(48)
gad20-209-fsp, rp2d
Lynch Syndrome
National Cancer Institute (NCI)
P1/2
CCC
(48)
Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV4-31*01 (89.9%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (85.3%)-IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1,glycoform alfa
Skin Squamous Cell Carcinoma
Hummingbird Bioscience
P1/2
CCC
(48)
Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV4-31*01 (89.9%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (85.3%)-IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1,glycoform alfa
Esophageal Squamous Cell Carcinoma
Hummingbird Bioscience
P1/2
CCC
(48)
Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV4-31*01 (89.9%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (85.3%)-IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1,glycoform alfa
Head And Neck Squamous Cell Carcinoma
Hummingbird Bioscience
P1/2
CCC
(48)
Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV4-31*01 (89.9%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (85.3%)-IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1,glycoform alfa
Nasopharyngeal Carcinoma
Hummingbird Bioscience
P1/2
CCC
(48)
Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV4-31*01 (89.9%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (85.3%)-IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1,glycoform alfa
Esophageal Cancer
Cancer Research UK
P1/2
CCC
(48)
Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV4-31*01 (89.9%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (85.3%)-IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1,glycoform alfa
Colorectal Cancer
Cancer Research UK
P1/2
CCC
(48)
Gamma4 heavy chain Homo sapiens (1-446) [VH (Homo sapiens IGHV4-39*01 (96.0%) -(IGHD) -IGHJ3*02 (100%), CDR-IMGT [10.7.12] (26-35.53-59.98-109)) (1-120)-Homo sapiens IGHG4*01, nG4m(a) CH2 L92, G4v5 h P10, G4v4 CH2 A1.3, A1.2 (CH1 (121-218), hinge 1-12 S10>P (228) (219-230), CH2 F1.3>A (234), L1.2>A (235), L92 (309) (231-340), CH3 (341-445), CHS K2>del (446)) (121-446)], (134-215')-disulfide with kappa light chain Homo sapiens (1'-215') [V-KAPPA (Homo sapiens IGKV1-33*01 (96.8%) -IGKJ4*01 (100%), CDR-IMGT[6.3.10] (27'-32'.50'-52'.89'-98')) (1'-108') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (154'), V101 (192') (109'-215')], dimer (226-226'':229-229'')-bisdisulfide, produced in Chinese hamster ovary (CHO)-K1SV cell line lacking the glutamine synthetase gene (GS-KO), glycoform alfa
Cutaneous Melanoma
Innovent Biologics (Suzhou) Co. Ltd.
P1/2
CCC
(48)
Garsorasib
Metastatic Neoplasm
Suzhou Genhouse Bio Co., Ltd.
P1/2
CCC
(48)
Gavo-Cel
Peritoneal Mesothelioma
TCR2 Therapeutics
P1/2
CCC
(48)
Gavo-Cel
Pleural Mesothelioma
TCR2 Therapeutics
P1/2
CCC
(48)
gb221
Spinal Muscular Atrophy, Type 1
Gemma Biotherapeutics
P1/2
CCC
(48)
gc101
Spinal Muscular Atrophy, Type II
GeneCradle Inc
P1/2
CCC
(48)
GC1134A
Fabry Disease
GC Biopharma Corp
P1/2
CCC
(48)
gc301
Glycogen Storage Disease Due To Acid Maltase Deficiency, Infantile Onset
GeneCradle Inc
P1/2
CCC
(48)
Gedatolisib
Triple-Negative Breast Carcinoma
Kari Wisinski
P1/2
CCC
(48)
Genistein
Amyloidosis
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
P1/2
CCC
(48)
gfh009
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Genfleet Therapeutics (Shanghai) Inc.
P1/2
CCC
(48)
gh21
Metastatic Neoplasm
Suzhou Genhouse Bio Co., Ltd.
P1/2
CCC
(48)
gi-101a
Nonpapillary Renal Cell Carcinoma
GI Innovation, Inc.
P1/2
CCC
(48)
gi-101a
Non-Small Cell Squamous Lung Carcinoma
GI Innovation, Inc.
P1/2
CCC
(48)
gi-102
Her2-Receptor Negative Breast Cancer
GI Innovation, Inc.
P1/2
CCC
(48)
Showing 1226 to 1250 of 6,308 assets
Previous
Page 50 of 253
Next
